Advances in immunotherapy for hepatocellular carcinoma
10.3760/cma.j.cn113884-20190127-00029
- VernacularTitle:肝细胞性肝癌免疫治疗研究进展
- Author:
Yanzhao ZHOU
1
;
Zhengzheng WANG
;
Qingjun LI
;
Xun CHEN
;
Ruili ZHU
;
Nanmu YANG
;
Jinxue ZHOU
Author Information
1. 郑州大学附属肿瘤医院 河南省肿瘤医院肝胆胰腺外科，郑州 450008
- From:
Chinese Journal of Hepatobiliary Surgery
2020;26(6):472-476
- CountryChina
- Language:Chinese
-
Abstract:
Hepatocellular carcinoma (HCC) is mostly treated by surgery combined with interventional therapy, chemotherapy, radiotherapy and local treatment. However, it often relapses after the operation. And the prognosis of advanced patients is poor, and the effective rate of chemotherapy and molecular targeted therapy is low. Recent studies indicated that the occurrence and progress of HCC are closely related to the immune function of the body. Immunotherapy, as a new type of tumor therapy, has drawn much attention. By improving the immunogenicity of tumor cells and the killing sensitivity of effector cells, it stimulates the immune function of the body, prolongs the progression-free survival time and the overall survival time of patients, and becomes an integral part of the comprehensive treatment of liver cancer. This article reviewd the progress in immunotherapy of HCC in the recent years.
